| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCDC134 |
| Uniprot No | Q9H6E4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-229aa |
| 氨基酸序列 | TLRTSLDPSLEIYKKMFEVKRREQLLALKNLAQLNDIHQQYKILDVMLKG LFKVLEDSRTVLTAADVLPDGPFPQDEKLKDAFSHVVENTAFFGDVVLRF PRIVHYYFDHNSNWNLLIRWGISFCNQTGVFNQGPHSPILSLMAQELGIS EKDSNFQNPFKIDRTEFIPSTDPFQKALREEEKRRKKEEKRKEIRKGPRI SRSQSELVDHHHHHH |
| 预测分子量 | 25 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCDC134重组蛋白的示例参考文献(注：内容为示例性质，实际文献可能需要进一步查证)：
1. **文献名称**: "Expression and functional characterization of recombinant CCDC134 in immune regulation"
**作者**: Zhang L, et al.
**摘要**: 研究报道了CCDC134重组蛋白在大肠杆菌中的高效表达与纯化，并验证其通过调控STAT3信号通路抑制T细胞过度活化，提示其在自身免疫疾病中的潜在应用。
2. **文献名称**: "CCDC134 recombinant protein suppresses tumor growth via modulating the JAK-STAT pathway"
**作者**: Wang Y, et al.
**摘要**: 通过体外实验证明，CCDC134重组蛋白可抑制多种癌细胞增殖，机制与阻断JAK-STAT信号传导相关，为癌症靶向治疗提供新思路。
3. **文献名称**: "Structural analysis and immunomodulatory activity of CCDC134 in vitro"
**作者**: Chen X, et al.
**摘要**: 解析了CCDC134重组蛋白的晶体结构，并发现其通过结合细胞表面受体激活下游抗炎因子表达，为开发新型免疫调节剂奠定基础。
**提示**：以上内容为模拟生成，实际文献可能存在差异。建议通过PubMed、Web of Science等平台以“CCDC134 recombinant protein”为关键词检索最新研究。
CCDC134 (Coiled-Coil Domain Containing Protein 134) is a protein encoded by the *CCDC134* gene, which has drawn attention in biomedical research due to its potential roles in immune regulation and cancer biology. Structurally, it contains characteristic coiled-coil domains, which are known to mediate protein-protein interactions and subcellular localization. Studies suggest that CCDC134 may function as a cytokine-like protein involved in modulating immune responses, particularly through the JAK-STAT signaling pathway. It has been implicated in enhancing T-cell activation and anti-tumor immunity, making it a candidate for immunotherapy research.
Recombinant CCDC134 protein is typically produced using expression systems like *E. coli* or mammalian cells, enabling researchers to study its biochemical properties and therapeutic potential. Preclinical studies highlight its ability to suppress tumor growth in murine models by promoting immune cell infiltration and cytokine production. Additionally, CCDC134 appears to interact with extracellular matrix components and cell surface receptors, suggesting roles in cellular adhesion or signaling crosstalk. Aberrant expression of CCDC134 has been observed in certain cancers and autoimmune disorders, linking it to disease progression or immune dysregulation.
Current research focuses on elucidating its precise molecular mechanisms, receptor partners, and clinical applications. Its recombinant form serves as a tool for developing diagnostic assays, therapeutic antibodies, or engineered immune modulators. Despite promising early findings, further validation in human trials is needed to assess its efficacy and safety. Overall, CCDC134 represents a novel target at the intersection of immunology and oncology, with potential implications for next-generation biologics.
×
